Platform

The Janux platform enables the rapid identification of TRACTr and TRACIr development candidates due to a modular design that provides multiple opportunities to rapidly develop therapeutics. The Janux pipeline targets multiple solid tumor indications including metastatic castrate-resistant prostate cancer, colorectal cancer, squamous cell carcinoma of the head and neck, triple-negative breast cancer, urothelial cancer, and non-small cell lung cancer.

Each of these tumor targets are clinically validated and implicated in solid tumors with high prevalence. We are also applying our proprietary technology to develop a costimulatory bispecific product candidate against programmed death-ligand 1 (PD-L1) and CD28 designed to further enhance the anti-tumor activity of T cells, which we believe has the potential to be used as a single-agent or in combination with our current TRACTr pipeline.

WHOLLY OWNED TRACTr PROGRAMSTargetsInitial IndicationsDiscoveryIND-EnablingPhase 1Phase 2Phase 3Anticipated Milestones
WHOLLY OWNED TRACTr PROGRAMS
JANX007PSMA x CD3 mCRPC

 

JANX007 is our novel TRACTr therapeutic targeting prostate-specific membrane antigen (PSMA) for the treatment of metastatic castration-resistant prostate cancer (mCPRC).

Learn More

JANX008EGFR x CD3 CRC, NSCLC, SCCHN

 

JANX008 is our novel TRACTr therapeutic targeting epidermal growth factor receptor (EGFR) for the treatment of multiple solid cancers including, metastatic colorectal cancer (mCRC), squamous cell carcinoma of the head and neck (SCCHN), and non-small cell lung cancer (NSCLC).

Learn More

TROP2-TRACTrTROP2 x CD3 TNBC, UC, NSCLC

 

Our TROP2-TRACTr is an TROP2xCD3 bispecific T cell engager designed to generate potent anti-tumor activity in solid tumor patients.

Learn More

WHOLLY OWNED TRACIr PROGRAMS
JANX009 PD-L1 x CD28 Solid Tumors

 

Our PD-L1xCD28 costimulatory bispecific program is designed to amplify existing T cell anti-tumor responses as well as TRACTr activity through a dual mechanism of (i) blocking tumor-expressed immunosuppressive signaling and (ii) activating T cell costimulatory signaling.

Learn More

DrugStage
JANX007
PSMA x CD3
Phase 1
JANX008
EGFR x CD3
IND-Enabling
TROP2-TRACTr
TROP2 x CD3
Discovery
JANX009
PD-L1 x CD28
Discovery

JANX007

JANX007 is our novel TRACTr therapeutic targeting prostate-specific membrane antigen (PSMA) for the treatment of metastatic castration-resistant prostate cancer (mCPRC).

Learn More

JANX008

JANX008 is our novel TRACTr therapeutic targeting epidermal growth factor receptor (EGFR) for the treatment of multiple solid cancers including, metastatic colorectal cancer (mCRC), squamous cell carcinoma of the head and neck (SCCHN), and non-small cell lung cancer (NSCLC).

Learn More

TROP2-TRACTr

Our TROP2-TRACTr is an TROP2xCD3 bispecific T cell engager designed to generate potent anti-tumor activity in solid tumor patients.

Learn More

JANX009

Our PD-L1xCD28 costimulatory bispecific program is designed to amplify existing T cell anti-tumor responses as well as TRACTr activity through a dual mechanism of (i) blocking tumor-expressed immunosuppressive signaling and (ii) activating T cell costimulatory signaling.

Learn More